[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-001", "question": "A 45-year-old male presents with syncope. ECG shows sinus rhythm with first-degree AV block and a right bundle branch block. Echocardiogram reveals a left ventricular ejection fraction (LVEF) of 42% with mild LV dilation. Genetic testing confirms a pathogenic variant in the LMNA gene (Lamin A/C). He has no history of sustained ventricular tachycardia. Which of the following is the most appropriate management?", "options": ["Implantation of a dual-chamber pacemaker", "Implantation of an implantable cardioverter-defibrillator (ICD)", "Implantation of an implantable loop recorder", "Initiation of Amiodarone", "Initiation of Metoprolol and reassessment of LVEF in 3 months"], "answer": "B", "answer_index": 1, "explanation": "Lamin A/C (LMNA) cardiomyopathy carries a disproportionately high risk of malignant ventricular arrhythmias and sudden cardiac death, often independent of the degree of LV dysfunction. Current guidelines recommend ICD implantation for patients with an LMNA mutation and risk factors such as AV block, male sex, or non-missense mutations, even if the LVEF is >35%. A pacemaker alone addresses the conduction disease but leaves the patient unprotected against the high risk of fatal ventricular arrhythmias.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient has a pathogenic mutation in the LMNA gene (encoding Lamin A/C), which causes a form of dilated cardiomyopathy associated with a very high risk of conduction system disease (AV block) and malignant ventricular arrhythmias.\n\nThe management of patients with *LMNA* mutations differs from standard dilated cardiomyopathy guidelines due to the elevated risk of sudden cardiac death (SCD) even before severe left ventricular dysfunction develops.\n\nAccording to the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death and the 2022 ESC Guidelines, risk stratification for *LMNA* cardiomyopathy identifies patients who benefit from early ICD implantation.\n\nCurrent recommendations state that ICD implantation is reasonable/beneficial (Class IIa) in patients with *LMNA* mutations who have:\n1.  LVEF < 45% (independent of heart failure severity).\n2.  Significant risk factors such as non-sustained VT, male sex, or non-missense mutations.\n3.  Indication for permanent pacing. Due to the high risk of ventricular arrhythmias, if a patient with *LMNA* requires pacing for AV block or bradycardia, they should receive an ICD rather than a standalone pacemaker to provide protection against SCD.\n\nIn this scenario:\n*   The patient has an LVEF of 42%, which falls below the 45% threshold typically used for *LMNA* patients (tighter than the 35% cutoff for general DCM).\n*   The patient is male (an independent risk factor for ventricular arrhythmias in *LMNA*).\n*   The patient presents with syncope and conduction system disease (1st-degree AV block and RBBB). Syncope in this context is highly concerning for intermittent high-grade AV block or ventricular arrhythmias.\n\nWhile the conduction abnormalities might suggest the need for pacing (Option A), a dual-chamber pacemaker alone provides no protection against the high risk of SCD from ventricular arrhythmias inherent to this condition with reduced LVEF. An implantable loop recorder (Option C) delays necessary therapy in a high-risk symptomatic patient. Medical therapy alone (Options D and E) is insufficient for SCD prevention in this genetic profile.\n\nTherefore, an ICD is the correct management to address both the potential need for pacing (if the device is a dual-chamber ICD) and, crucially, the risk of sudden cardiac death.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-002", "question": "A 68-year-old male presents with a 3-week history of brief, involuntary jerking movements of his right face and arm, occurring up to 40 times per day. He remains conscious during these events. Interictal EEG and brain MRI are unremarkable. He is beginning to show signs of short-term memory impairment. Which of the following is the most appropriate initial treatment?", "options": ["Levetiracetam", "Carbamazepine", "Intravenous Methylprednisolone", "Tissue Plasminogen Activator (tPA)", "Haloperidol"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation is classic for faciobrachial dystonic seizures (FBDS), which are pathognomonic for Anti-LGI1 encephalitis (a form of limbic encephalitis). These seizures are characteristically resistant to standard anti-epileptic drugs but respond dramatically to immunotherapy (steroids, IVIG). Early recognition and treatment with immunotherapy are crucial to prevent the progression to severe cognitive impairment and full-blown limbic encephalitis.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient is presenting with faciobrachial dystonic seizures (FBDS), which are brief, frequent, stereotyped movements of the face and arm. These seizures are pathognomonic for anti-LGI1 (leucine-rich glioma-inactivated 1) encephalitis, a form of autoimmune limbic encephalitis.\n\n1.  Clinical Features: The description of \"brief, involuntary jerking movements of his right face and arm\" occurring many times a day (up to 40) is the classic presentation of FBDS. The preservation of consciousness is typical.\n2.  Progression: These seizures often precede the onset of cognitive impairment (limbic encephalitis) by weeks. The patient is already beginning to show signs of memory impairment.\n3.  Treatment: FBDS are typically resistant to standard anti-seizure medications (ASMs) like Levetiracetam. While sodium channel blockers like Carbamazepine may offer some symptomatic control, they do not address the underlying autoimmune pathology. The most appropriate and effective initial treatment is immunotherapy (such as corticosteroids, IVIG, or plasma exchange). Rapid initiation of immunotherapy (e.g., Intravenous Methylprednisolone) has been shown to cease the seizures and prevent or improve the associated cognitive decline.\n\nTherefore, treating the underlying autoimmune cause is the priority.\n\n*   Levetiracetam (A) and Carbamazepine (B) are anti-seizure medications. While Carbamazepine is sometimes noted to be more effective than other ASMs for FBDS, immunotherapy is superior and critical to prevent permanent cognitive deficits.\n*   tPA (D) is for acute ischemic stroke, which this is not.\n*   Haloperidol (E) is an antipsychotic and not indicated.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-003", "question": "A 55-year-old female is admitted to the ICU with sepsis and severe malnutrition. She has a history of chronic back pain managed with acetaminophen. Arterial blood gas shows pH 7.26, pCO2 28 mmHg, HCO3 12 mEq/L. Serum chemistry shows Na 140, Cl 104, BUN 18, Cr 0.8. Lactate is 1.1 mmol/L. Serum ketones are negative. Measured serum osmolality is 295 mOsm/kg (calculated 290). Which of the following is the most likely etiology of her metabolic acidosis?", "options": ["Methanol intoxication", "D-lactic acidosis", "Pyroglutamic acidosis (5-oxoproline accumulation)", "Propylene glycol toxicity", "Salicylate toxicity"], "answer": "C", "answer_index": 2, "explanation": "The patient has a high anion gap metabolic acidosis (AG = 24) with a normal lactate, no ketones, normal renal function, and a normal osmol gap (ruling out toxic alcohols like methanol or propylene glycol). The combination of chronic acetaminophen use, sepsis, and malnutrition leads to glutathione depletion, causing a disruption in the gamma-glutamyl cycle and accumulation of 5-oxoproline (pyroglutamic acid). This is an under-recognized cause of high anion gap acidosis in this specific patient population.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient presents with a High Anion Gap Metabolic Acidosis (HAGMA).\nAnion Gap = $Na - (Cl + HCO_3) = 140 - (104 + 12) = 24$ mEq/L.\nA normal anion gap is typically 8-12 mEq/L.\n\nWe must evaluate the causes of HAGMA (GOLD MARK / MUDPILES) in the context of the available data:\n1.  Lactic Acidosis: The L-lactate is 1.1 mmol/L (normal).\n2.  Ketoacidosis: Serum ketones are negative.\n3.  Uremia: BUN and Creatinine are normal.\n4.  Toxic Alcohols (Methanol/Ethylene Glycol): These substances typically cause an elevated osmolar gap (>10 mOsm/kg).\n    *   Osmolar Gap = Measured Osmolality - Calculated Osmolality.\n    *   Gap = 295 - 290 = 5 mOsm/kg.\n    *   The gap is normal, making methanol (Option A) and ethylene glycol toxicity unlikely.\n5.  Propylene Glycol (Option D): Typically associated with high-dose IV infusions of medications like lorazepam or diazepam. It often causes an elevated osmolar gap and can elevate lactate levels (often falsely measured as L-lactate or causing true lactic acidosis). Given the normal lactate and normal osmolar gap, this is less likely.\n6.  Salicylate Toxicity (Option E): Usually presents with a mixed acid-base disorder: primary respiratory alkalosis and HAGMA. Using Winters' formula ($PCO_2 = 1.5 \\times HCO_3 + 8 \\pm 2$), the expected PCO2 is $1.5(12) + 8 = 26 \\pm 2$ (24-28 mmHg). The patient's PCO2 is 28 mmHg, indicating appropriate respiratory compensation for metabolic acidosis rather than a primary respiratory alkalosis (which would drive PCO2 lower). Furthermore, the history specifies acetaminophen, not aspirin.\n7.  D-Lactic Acidosis (Option B): Caused by bacterial overgrowth in patients with short bowel syndrome or jejunoileal bypass. This patient does not have the suggestive surgical history.\n8.  Pyroglutamic Acidosis (Option C): Also known as 5-oxoproline acidosis. This creates a HAGMA with a normal osmolar gap. The pathophysiology involves the interruption of the gamma-glutamyl cycle due to glutathione depletion.\n    *   Risk Factors present in this patient:\n        *   Chronic Acetaminophen use: Consumes glutathione stores.\n        *   Malnutrition: Reduces the supply of amino acids necessary for glutathione synthesis.\n        *   Sepsis: Increases oxidative stress, further depleting glutathione.\n        *   Female gender: This condition is reported more frequently in women.\n    *   When glutathione is depleted, feedback inhibition on the enzyme gamma-glutamyl cysteine synthetase is lost, leading to the overproduction of gamma-glutamyl cysteine, which is then converted into 5-oxoproline (pyroglutamic acid). This acid accumulates, causing the anion gap acidosis.\n\nGiven the triad of sepsis, malnutrition, and chronic acetaminophen use in a patient with HAGMA, normal lactate, negative ketones, and a normal osmolar gap, pyroglutamic acidosis is the most likely etiology.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-004", "question": "A 34-year-old male presents with progressive dyspnea. He has a BMI of 17 kg/m2. Chest radiography shows apical pleural thickening. High-resolution CT demonstrates upper-lobe predominant subpleural fibrosis and a flattened chest configuration ('platythorax'). He has no history of asbestos exposure or connective tissue disease. Which of the following is the most likely diagnosis?", "options": ["Idiopathic Pulmonary Fibrosis (IPF)", "Pleuroparenchymal Fibroelastosis (PPFE)", "Chronic Hypersensitivity Pneumonitis", "Lymphangioleiomyomatosis (LAM)", "Pulmonary Alveolar Proteinosis"], "answer": "B", "answer_index": 1, "explanation": "Pleuroparenchymal Fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by fibrosis of the visceral pleura and subpleural lung parenchyma, predominantly in the upper lobes. The radiographic hallmark is the 'platythorax' (flattening of the chest cage) due to fibrosis progression. This contrasts with IPF (lower lobe predominant) and Hypersensitivity Pneumonitis (mosaic attenuation, centrilobular nodules).", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Based on the clinical presentation and imaging findings, the diagnosis is Pleuroparenchymal Fibroelastosis (PPFE).\n\nHere is the breakdown of the key features from the vignette:\n1.  Patient Demographics: A 34-year-old male. PPFE can affect a wide age range but is often seen in younger patients compared to Idiopathic Pulmonary Fibrosis (IPF).\n2.  Low BMI (17 kg/m2): Patients with PPFE typically have a slender build and low body mass index (\"flat chest\").\n3.  Chest Radiography/HRCT:\n    *   Apical pleural thickening: This is a hallmark of PPFE.\n    *   Upper-lobe predominant subpleural fibrosis: The disease process involves the pleura and subpleural lung parenchyma, specifically in the upper lobes.\n    *   Platythorax: This refers to a flattened anteroposterior diameter of the chest, acquired as the fibrosis progresses and contracts. This is a highly characteristic sign of PPFE.\n\nWhy the other options are incorrect:\n*   A. Idiopathic Pulmonary Fibrosis (IPF): Typically affects older adults (>60 years) and presents with lower-lobe predominant fibrosis and honeycombing (UIP pattern).\n*   C. Chronic Hypersensitivity Pneumonitis: While it can cause upper-lobe fibrosis, it is often associated with mosaic attenuation, air trapping, and centrilobular nodules. It does not typically cause platythorax or the distinct apical pleural thickening seen in PPFE without specific exposures.\n*   D. Lymphangioleiomyomatosis (LAM): Almost exclusively affects women of childbearing age and presents with diffuse thin-walled cysts, not apical fibrosis.\n*   E. Pulmonary Alveolar Proteinosis: Presents with a \"crazy-paving\" pattern (ground-glass opacities with septal thickening) and is generally not a fibrotic disease at presentation.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-005", "question": "A 24-year-old African American male presents with cyanosis and shortness of breath after taking dapsone for a skin lesion. Pulse oximetry reads 85% and does not improve with supplemental oxygen. Arterial blood gas shows a normal PaO2 but methemoglobin level is 18%. He has a known history of hemolysis after ingesting fava beans. Which of the following is the most appropriate treatment?", "options": ["Methylene Blue 1 mg/kg IV", "Ascorbic Acid (Vitamin C) IV", "Hydroxocobalamin IV", "Hyperbaric Oxygen Therapy", "Sodium Thiosulfate IV"], "answer": "B", "answer_index": 1, "explanation": "The patient has methemoglobinemia precipitated by dapsone. However, his history of hemolysis with fava beans strongly suggests Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Methylene blue is contraindicated in G6PD deficiency because it requires NADPH (generated by G6PD) to reduce methemoglobin; without G6PD, methylene blue is ineffective and can induce severe hemolysis. Ascorbic acid (Vitamin C) or exchange transfusion is the appropriate management.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This question describes a case of acquired methemoglobinemia (indicated by cyanosis, low pulse oximetry saturation with a spectral gap, normal PaO2 on ABG, and elevated methemoglobin level) precipitated by dapsone.\n\nA crucial component of the patient's history is the \"hemolysis after ingesting fava beans.\" This is a classic presentation for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.\n\nAnalysis of Options:\n*   A. Methylene Blue: This is the standard first-line antidote for symptomatic methemoglobinemia. It works by increasing the activity of NADPH methemoglobin reductase. However, this enzyme requires NADPH, which is generated by G6PD. In patients with G6PD deficiency, NADPH levels are insufficient. Consequently, Methylene Blue is ineffective and can actually act as an oxidant, precipitating severe hemolysis (hemolytic anemia) and potentially worsening the methemoglobinemia. Therefore, it is contraindicated in this patient.\n*   B. Ascorbic Acid (Vitamin C): In patients with G6PD deficiency where Methylene Blue is contraindicated, moderate to high-dose intravenous Vitamin C is the appropriate alternative pharmacological treatment. It reduces methemoglobin to hemoglobin via a non-enzymatic pathway. While its onset of action is slower than Methylene Blue, it is safe for G6PD-deficient patients.\n*   C. Hydroxocobalamin: This is an antidote for cyanide poisoning.\n*   D. Hyperbaric Oxygen Therapy: This is generally reserved for severe cases (e.g., fluid-refractory shock, end-organ damage) or those unresponsive to other treatments. While it is an option if biochemical treatments fail, Ascorbic Acid is the standard next-line pharmacological choice tested in this context for a stable patient with moderate levels (18%).\n*   E. Sodium Thiosulfate: This is used for cyanide poisoning or calciphylaxis.\n\nBecause Methylene Blue is contraindicated due to the patient's G6PD deficiency, the correct treatment is Ascorbic Acid.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-006", "question": "A 14-year-old boy with a history of exercise-induced syncope is diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) confirmed by an RyR2 mutation. He is compliant with high-dose Nadolol. A repeat exercise stress test shows a reduction in arrhythmia burden, but he still develops runs of bidirectional ventricular tachycardia at peak exertion. Which of the following is the best next step in management?", "options": ["Switch Nadolol to Metoprolol Succinate", "Add Flecainide", "Perform Radiofrequency Ablation of the ventricular focus", "Implant a dual-chamber pacemaker", "Add Verapamil"], "answer": "B", "answer_index": 1, "explanation": "In patients with CPVT who have breakthrough arrhythmias despite optimal beta-blocker therapy (preferably Nadolol or Propranolol), the addition of Flecainide is the guideline-recommended next step. Flecainide has a direct blocking effect on the cardiac ryanodine receptor (RyR2), addressing the underlying mechanism. Radiofrequency ablation is generally ineffective due to the polymorphic/multifocal nature of the arrhythmia.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This question describes a patient with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), confirmed by an RyR2 mutation, who is symptomatic (or at least has significant arrhythmia burden) despite optimal beta-blocker therapy.\n\n1.  Diagnosis and Pathophysiology: CPVT is an inherited channelopathy, most commonly caused by mutations in the Ryanodine Receptor 2 (RyR2) gene. It leads to intracellular calcium overload during adrenergic stimulation, causing delayed afterdepolarizations (DADs) and triggering bidirectional or polymorphic ventricular tachycardia.\n\n2.  Current Management: The patient is taking Nadolol. Non-selective beta-blockers like Nadolol and Propranolol are the first-line therapy for CPVT and are superior to beta-1 selective agents (like Metoprolol). Since the patient is already compliant with high-dose Nadolol, the first line of defense is maximized.\n\n3.  Refractory Disease: The patient demonstrates \"breakthrough\" arrhythmias (bidirectional VT) on exercise testing. Management of CPVT refractory to beta-blockers involves intensifying medical therapy or performing Left Cardiac Sympathetic Denervation (LCSD).\n\n4.  Evaluating the Options:\n    *   A. Switch Nadolol to Metoprolol Succinate: This is contraindicated or at least ill-advised. Selective beta-blockers are less effective in CPVT than non-selective ones. Switching would likely worsen control.\n    *   B. Add Flecainide: Flecainide is a Class Ic antiarrhythmic that significantly reduces ventricular arrhythmias in CPVT patients uncontrolled by beta-blockers alone. Its mechanism in CPVT involves blocking cardiac sodium channels (raising the threshold for DAD-triggered action potentials) and, uniquely, directly inhibiting the RyR2 channel to prevent calcium release. Clinical guidelines recommend adding Flecainide for patients with recurrent syncope or sustained VT despite beta-blocker therapy.\n    *   C. Perform Radiofrequency Ablation: CPVT is a global problem of cardiac myocytes involving calcium handling; it does not usually have a single focal origin that can be ablated. Ablation is not a standard treatment.\n    *   D. Implant a dual-chamber pacemaker: While bradycardia can occur with high-dose beta-blockers, pacing alone does not treat the ventricular arrhythmia substrate in CPVT.\n    *   E. Add Verapamil: Calcium channel blockers have been studied in CPVT but have generally shown limited efficacy compared to Flecainide. They are not the preferred second-line agent.\n\nTherefore, the addition of Flecainide is the most appropriate next step to control the arrhythmia burden.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-007", "question": "A 26-year-old female with a history of sensorineural hearing loss and short stature presents with acute onset aphasia and right-sided hemiparesis. MRI shows a T2-hyperintense lesion in the left temporal lobe that does not conform to a vascular territory. Serum lactate is elevated. Which of the following agents is indicated for the acute management of this condition?", "options": ["Intravenous Tissue Plasminogen Activator (tPA)", "Intravenous Arginine", "Intravenous Heparin", "High-dose Aspirin", "Plasma Exchange"], "answer": "B", "answer_index": 1, "explanation": "The clinical picture (stroke-like episode not respecting vascular territories, hearing loss, elevated lactate) is classic for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes). The stroke-like episodes are due to metabolic failure and microvascular angiopathy (nitric oxide deficiency), not thrombotic occlusion. Intravenous Arginine is the recommended acute treatment to improve nitric oxide availability and cerebral blood flow. tPA is not indicated and could be harmful.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical presentation described in the vignette is classic for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes).\n\n1.  Diagnosis: The patient is a young female with short stature and sensorineural hearing loss, which are common features of mitochondrial disorders. She presents with a \"stroke-like episode\" (acute aphasia and hemiparesis). The key distinguishing features from a typical ischemic stroke are the elevated serum lactate and the MRI findings (T2-hyperintense lesion that does *not* conform to a specific vascular territory).\n2.  Pathophysiology: In MELAS, stroke-like episodes are thought to result from a combination of mitochondrial energy failure and angiopathy. Specifically, there is a deficiency of nitric oxide (NO), leading to impaired vasodilation in the cerebral microvasculature.\n3.  Management:\n    *   Intravenous Arginine (Option B): L-arginine is a precursor to nitric oxide. Administration of intravenous L-arginine during the acute phase of a stroke-like episode in MELAS is recommended to increase nitric oxide levels, improve cerebral blood flow, and reduce the severity of the brain injury. Oral arginine is also used for prophylaxis.\n    *   tPA (Option A): Tissue plasminogen activator is used for ischemic strokes caused by thromboembolism. Since the pathophysiology in MELAS is metabolic and microvascular rather than a large vessel occlusion by a clot, tPA is not indicated and could be dangerous.\n    *   Heparin (Option C) and Aspirin (Option D): These are standard treatments for thrombotic/embolic strokes but do not address the underlying metabolic angiopathy of MELAS.\n    *   Plasma Exchange (Option E): This is used for autoimmune neurological conditions (e.g., Guillain-Barré syndrome, Myasthenia Gravis), which is not the diagnosis here.\n\nTherefore, intravenous arginine is the indicated agent for the acute management of this condition.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-008", "question": "A 32-year-old female is evaluated for palpitations. Labs reveal a TSH of 7.2 mIU/L (High) and Free T4 of 2.9 ng/dL (High). An MRI of the pituitary shows a 5mm hypoenhancing lesion. Sex Hormone Binding Globulin (SHBG) levels are elevated. Which of the following is the most likely diagnosis?", "options": ["Resistance to Thyroid Hormone (RTH) beta", "TSH-secreting pituitary adenoma (TSHoma)", "Graves' disease", "Familial Dysalbuminemic Hyperthyroxinemia", "Heterophile antibody interference"], "answer": "B", "answer_index": 1, "explanation": "Both RTH and TSHoma present with inappropriate TSH secretion (high T4, non-suppressed TSH). The key differentiator is the peripheral tissue response. In TSHoma, peripheral tissues (like the liver) are sensitive to the high thyroid hormone levels, resulting in elevated markers of thyroid action such as Sex Hormone Binding Globulin (SHBG). In RTH, the peripheral tissues are resistant, so SHBG levels are typically normal. The pituitary lesion supports TSHoma, but incidentalomas are common; the metabolic profile (high SHBG) confirms the diagnosis.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Here is the step-by-step reasoning for the correct diagnosis:\n\n1.  Analyze the Thyroid Function Tests: The patient has an elevated TSH (7.2 mIU/L) and an elevated Free T4 (2.9 ng/dL). This constellation of findings—elevated thyroid hormones with a non-suppressed (in this case, elevated) TSH—is known as the Syndrome of Inappropriate TSH Secretion (SITSH). This immediately rules out primary hyperthyroidism (like Graves' disease), where TSH would be suppressed (<0.01 mIU/L).\n\n2.  Differential Diagnosis for SITSH: The two main etiologies to distinguish are a TSH-secreting pituitary adenoma (TSHoma) and Resistance to Thyroid Hormone (RTH) syndrome (specifically RTH beta).\n\n3.  Evaluate Clinical Features and Markers:\n    *   MRI: The patient has a 5mm pituitary lesion. While incidentalomas are possible in RTH, a distinct lesion supports the possibility of an adenoma.\n    *   Symptoms: The patient has palpitations, suggesting a thyrotoxic state. Patients with TSHomas are clinically thyrotoxic because their thyroid releases excess hormones that act on normal peripheral tissues. Patients with RTH are often clinically euthyroid (or hypothyroid in some tissues) because their tissues are resistant to the high hormone levels, though tachycardia can occur via TR$\\alpha$ receptors in the heart.\n    *   Sex Hormone Binding Globulin (SHBG): This is the key discriminator in this scenario. Thyroid hormone stimulates the liver to produce SHBG.\n        *   In TSHoma, the peripheral tissues (including the liver) are normal and sensitive to thyroid hormone. The high circulating T4/T3 levels stimulate the liver to produce excess SHBG, leading to elevated levels.\n        *   In RTH, the liver receptors (TR$\\beta$) are mutated and resistant to thyroid hormone. Despite high circulating T4/T3, the liver does not produce excess SHBG. Therefore, SHBG levels are typically normal or low.\n\n4.  Conclusion: The combination of SITSH, thyrotoxic symptoms (palpitations), a pituitary lesion on MRI, and crucially, elevated SHBG, points to a TSH-secreting pituitary adenoma.\n\n*   Option A (RTH) is incorrect because SHBG would be normal or low due to hepatic resistance.\n*   Option C (Graves' disease) is incorrect because TSH would be suppressed.\n*   Option D (FDH) is incorrect because TSH is usually normal, and the patient is usually clinically euthyroid.\n*   Option E (Interference) is less likely given the concordance of symptoms, imaging, and specific biomarker patterns (high SHBG).\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-009", "question": "A 48-year-old male who works as a tool grinder presents with chronic dry cough and dyspnea. Bronchoalveolar lavage (BAL) reveals multinucleated giant cells that appear to be engulfing other cells ('cannibalistic' giant cells). Which of the following exposures is most likely responsible for this finding?", "options": ["Silica", "Asbestos", "Cobalt", "Beryllium", "Coal dust"], "answer": "C", "answer_index": 2, "explanation": "The presence of 'cannibalistic' multinucleated giant cells in BAL or biopsy is pathognomonic for Hard Metal Lung Disease (Giant Cell Interstitial Pneumonia). This is caused by exposure to Cobalt, often in the form of tungsten carbide alloy used in tool grinding, diamond polishing, or saw sharpening. Beryllium causes granulomas similar to sarcoidosis, not GIP.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Here is the step-by-step reasoning for the answer:\n\n1.  Identify the Clinical Presentation: The patient presents with respiratory symptoms (cough, dyspnea) and has a specific occupational history as a \"tool grinder.\" Tool grinding often involves working with hard metals, specifically tungsten carbide.\n\n2.  Analyze the Pathological Findings: The Bronchoalveolar lavage (BAL) reveals multinucleated giant cells that appear to be engulfing other cells. These are described as \"cannibalistic\" giant cells.\n\n3.  Connect Pathology to Disease: The presence of bizarre, multinucleated giant cells that engulf other inflammatory cells (cannibalism) is the hallmark histologic feature of Giant Cell Interstitial Pneumonia (GIP).\n\n4.  Connect Disease to Exposure: Giant Cell Interstitial Pneumonia is virtually pathognomonic for Hard Metal Lung Disease. Hard metal is an alloy typically composed of tungsten carbide with cobalt acting as the binder matrix. While tungsten is present, cobalt is the primary agent responsible for the interstitial lung disease and the specific GIP reaction.\n\n5.  Evaluate the Options:\n    *   A. Silica: Causes silicosis, characterized by concentric hyalinized nodules.\n    *   B. Asbestos: Causes asbestosis, characterized by interstitial fibrosis and asbestos fibers/ferruginous bodies.\n    *   C. Cobalt: The causative agent of Hard Metal Lung Disease, which manifests as GIP with cannibalistic giant cells.\n    *   D. Beryllium: Causes chronic beryllium disease, characterized by non-caseating granulomas similar to sarcoidosis.\n    *   E. Coal dust: Causes coal workers' pneumoconiosis, characterized by coal macules and dust-laden macrophages.\n\n6.  Conclusion: The combination of the occupation (exposure to hard metal dust) and the specific finding of cannibalistic giant cells points to Cobalt exposure.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-010", "question": "A 52-year-old male presents to the ED 2 hours after ingesting a massive overdose of sustained-release Verapamil. He is hypotensive (BP 60/40 mmHg) and bradycardic (HR 38 bpm). He remains hypotensive despite 3 liters of crystalloid, IV Calcium Gluconate, and IV Glucagon. Which of the following is the most appropriate next therapeutic intervention?", "options": ["High-dose Insulin Euglycemia therapy", "Transvenous Pacing", "Hemodialysis", "IV Amiodarone", "IV Lipid Emulsion (20%)"], "answer": "A", "answer_index": 0, "explanation": "High-dose Insulin Euglycemia (HIE) is the recommended therapy for severe calcium channel blocker toxicity refractory to initial measures (fluids, calcium). Insulin has a positive inotropic effect and improves myocardial glucose utilization in the stressed heart. While lipid emulsion is a salvage therapy, HIE has stronger evidence as a first-line pharmacologic support after calcium/fluids. Transvenous pacing often fails to capture or improve cardiac output in severe CCB poisoning due to global myocardial depression.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "In the management of severe Calcium Channel Blocker (CCB) overdose, specifically with Verapamil (a non-dihydropyridine CCB), the clinical effects include severe vasodilation, negative inotropy (decreased contractility), and negative chronotropy (bradycardia).\n\nHere is the evaluation of the options provided:\n\n*   A. High-dose Insulin Euglycemia therapy (HIET): This is the correct choice. When a patient remains hypotensive despite fluid resuscitation and IV calcium, HIET is considered the first-line adjuvant therapy. While the exact mechanism is not fully understood, it is believed to increase myocardial contractility by improving glucose uptake in cardiac myocytes (which shift to glucose metabolism during stress) and by direct positive inotropic effects. It is superior to glucagon and vasopressors alone for improving cardiac output in severe CCB toxicity.\n*   B. Transvenous Pacing: While the patient is bradycardic, the primary driver of shock in massive Verapamil overdose is myocardial depression and vasodilation. Electrical pacing may achieve electrical capture, but it frequently fails to produce mechanical capture (contraction) because the calcium channels required for excitation-contraction coupling are blocked. Therefore, treating the cellular metabolic/inotropic capability (via HIET) is prioritized.\n*   C. Hemodialysis: Verapamil is highly protein-bound and has a large volume of distribution, making it not amenable to removal by hemodialysis.\n*   D. IV Amiodarone: This is contraindicated. Amiodarone is an antiarrhythmic that has calcium channel blocking (Class IV) and beta-blocking (Class II) properties. Administering it would exacerbate the hypotension and bradycardia, potentially causing cardiac arrest.\n*   E. IV Lipid Emulsion (20%): Lipid emulsion therapy is a valid treatment for lipophilic drug overdoses (like Verapamil), acting as a \"lipid sink.\" However, current toxicology guidelines generally reserve lipid emulsion for patients who are refractory to other measures (like HIET and vasopressors) or are in a peri-arrest state. HIET is typically initiated before lipid emulsion in a stable but critical patient like this.\n\nThe answer is (A)"}]